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Abstract
Background: The use of gene expression in venous blood either as a pharmacodynamic marker in clinical trials
of drugs or as a diagnostic test requires knowledge of the variability in expression over time in healthy volunteers.
Here we defined a normal range of gene expression over 6 months in the blood of four cohorts of healthy men
and women who were stratified by age (22–55 years and > 55 years) and gender.
Methods: Eleven immunomodulatory genes likely to play important roles in inflammatory conditions such as
rheumatoid arthritis and infection in addition to four genes typically used as reference genes were examined by
quantitative reverse transcription-polymerase chain reaction (qRT-PCR), as well as the full genome as
represented by Affymetrix HG U133 Plus 2.0 microarrays.
Results: Gene expression levels as assessed by qRT-PCR and microarray were relatively stable over time with
~2% of genes as measured by microarray showing intra-subject differences over time periods longer than one
month. Fifteen genes varied by gender. The eleven genes examined by qRT-PCR remained within a limited
dynamic range for all individuals. Specifically, for the seven most stably expressed genes (CXCL1, HMOX1, IL1RN,
IL1B, IL6R, PTGS2, and TNF), 95% of all samples profiled fell within 1.5–2.5 Ct, the equivalent of a 4- to 6-fold
dynamic range. Two subjects who experienced severe adverse events of cancer and anemia, had microarray gene
expression profiles that were distinct from normal while subjects who experienced an infection had only slightly
elevated levels of inflammatory markers.
Conclusion: This study defines the range and variability of gene expression in healthy men and women over a
six-month period. These parameters can be used to estimate the number of subjects needed to observe significant
differences from normal gene expression in clinical studies. A set of genes that varied by gender was also identified
as were a set of genes with elevated expression in a subject with iron deficiency anemia and another subject being
treated for lung cancer.
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Background
Gene expression profiling studies in venous blood are
used to explore transcriptional differences between dis-
eased and healthy individuals, identify biomarkers that
may identify the appropriate therapy for individual
patients, monitor a therapy and pharmacodynamic
responses to new drugs, or define prognosis. For example,
tumor molecular profiles have been identified that select
preferred therapy and predict recurrence [1-3]. For
autoimmune diseases, where the disease tissue is not read-
ily accessible, peripheral blood has become a surrogate
tissue by default [4]. Venous blood contains cells that will
migrate into and/or have migrated from the inflamed tis-
sue, potentially allowing the identification of patients
with disease by expression profiling of whole blood. To
date, studies of rheumatoid arthritis, systemic lupus ery-
thematosus (SLE), Crohn's disease, and multiple sclerosis
(MS) patients have identified expression profiles that may
be useful in diagnosis [5,6].
Knowledge of the variability of gene expression over time
in healthy men and women will help in the design of
studies where drugs are expected to modulate gene expres-
sion in the diseased population. It will be particularly
important to clearly establish the extent of normal varia-
tion for cases where the difference between normal and
diseased gene expression profiles is subtle.
Clinical studies need to control for multiple sources of
variability since gene expression can be influenced by psy-
chological stress [7,8], exercise [9,10] and eating [11]. In
vitro, inflammation markers are rapidly induced in
peripheral blood mononuclear cells (PBMC) by infectious
agents [12-14]. In vivo gene expression profiles of individ-
uals exposed to a bacterial toxin appeared to be different
from those of healthy individuals not exposed to the toxin
[15]. Gene expression is also sensitive to the method by
which the RNA from blood is isolated [16,17].
Several previous studies have examined gene expression
in the peripheral blood of normal individuals [15,18-21].
These investigators found inter-individual variation as
well as genes that uniquely identified the subjects being
studied. The results were obtained using either peripheral
blood mononuclear cells (PBMC) or whole blood. Gene
expression profiles differ greatly among the different
blood cell types [22,23]. However, the isolation of the dif-
ferent cell types requires capable laboratories that are not
always available at all centers involved in large clinical tri-
als. Whole blood can be sampled reliably with the PAX-
gene Blood RNA System [24,25]. Thus, the studies here
were carried out using this collection method.
The gene expression studies mentioned previously were
largely limited to a single platform for assays (microarray
or qRT-PCR), small numbers of subjects with analyses
often restricted to a short sampling time frame, or even a
single time point [15,18-21]. This study represents the
largest reported study of longitudinal genomic sampling
utilizing both microarray and qRT-PCR in an age and gen-
der stratified healthy patient population, to the best of our
knowledge. Moreover, the study was performed under
controlled conditions with all samples drawn in the
morning from fasted individuals at fixed times relative to
the start of the study.
The present study extends the information base for
healthy individuals by measuring the stability and
dynamic range of gene expression in healthy subjects over
an extended period of time, six months. qRT-PCR was
used to define the range of gene expression in 28 individ-
uals. Eleven immunomodulatory genes likely to play
important roles in inflammatory conditions and four ref-
erence genes were examined. In addition, 22 subjects were
assessed by high-density oligonucleotide microarray, two
of whom experienced a severe adverse event during the
six-month study period.
Methods
The study was conducted in accordance with good clinical
practice, the Declaration of Helsinki, and appropriate reg-
ulatory guidelines. An independent ethics committee
approved the protocol. Subjects gave written informed
consent to participate in the study.
Subjects
Blood samples were obtained from 80 healthy volunteers
enrolled at a single site in Strasbourg, France. All subjects
were enrolled in January and early February, 2003 and
had their last visit in August. Subjects were enrolled into
one of four cohorts:
￿ Cohort 1: males 20–55 years of age
￿ Cohort 2: males > 55 years of age
￿ Cohort 3: females 20–55 years of age
￿ Cohort 4: females > 55 years of age
Subjects were enrolled in the study if they were at least 20
years of age and were healthy, as determined by medical
history, physical examination, and standard laboratory
test values. Exclusion criteria included abnormal labora-
tory test results, BMI > 32, hypertension, and a positive
urine pregnancy test, or positive urine HCV, HBV or HIV
test. Any subject who had a concomitant disease or condi-
tion that could interfere with clinical evaluations, was an
active smoker, or was taking medication on a regular basisBMC Medical Genomics 2009, 2:33 http://www.biomedcentral.com/1755-8794/2/33
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was also excluded. Former smoking status was not cap-
tured.
A subset of 20 subjects was randomly selected from this
study population for microarray analysis. The subset con-
sisted of five subjects from each cohort. Two additional
subjects who suffered from serious adverse events during
the study were added subsequently. Samples from those
22 subjects were taken at five time points (Baseline, Day
14, Day 28, Day 90 and Day 180).
Quantitative RT-PCR was originally performed on all 80
subjects at each of the five time points for all analytes
described in the study. An analysis of the data revealed
that mean gene expression in all analytes varied signifi-
cantly by time point. Due to flaws in the initial experi-
mental design, we could not discern the degree to which
the differences were attributable to a true biological effect
(e.g. a seasonal effect of gene expression) or experimental
bias (e.g. a "batch" effect).
The qPCR study was therefore repeated with 28 subjects
chosen at random from the larger set of 80 where suffi-
cient RNA remained. The 28-subject study was designed to
distinguish between biological and experimental variabil-
ity, and to minimize experimental variability. The 28 sub-
jects were assayed by qRT-PCR at four time points
(Baseline, Day 28, Day 90 and Day 180). Samples from
eight subjects were analyzed on both qRT-PCR and micro-
array platforms.
RNA processing and quantitation
Whole blood (2.5 mL) was collected into PAXgene tubes
(Becton-Dickinson Diagnostics; Hombrechtikon, Switzer-
land) and frozen immediately at -20°C. The tubes were
shipped frozen and stored at -80°C for a period ranging
from one week to six months before RNA was extracted.
RNA extractions were performed in batches in the order in
which the PAXgene tubes were received. Total RNA was
extracted using the PAXgene 96 Blood RNA kit (Qiagen;
Hilden, Germany) according to the manufacturer's
instructions. RNA quality was assessed on an Agilent Bio-
analyzer 2100 (Agilent Technologies; Palo Alto, CA). Any
RNA sample with an RNA integrity number (RIN) < 6.5
was rejected and a replacement sample was obtained from
a replicate PAXgene tube. The mean yield of RNA from all
extractions with RIN ≥ 6.5 was 7.0 μg per tube (1 SD = 2.6
μg).
Quantitative RT-PCR
Quantitative RT-PCR assays used the fluorescent dye SYBR
Green to monitor amplicon formation in a one step for-
mat in which the RT step was performed in the same tube
as the PCR. All 384-well plates were profiled on an ABI
Prism 7900 HT Sequence Detection System (Applied Bio-
systems Inc.; Foster City, CA). All reactions were per-
formed with a single reagent lot. The cycling parameters
were as follows: Step 1: 50°C 2 min for Uracyl-N-Glycosy-
lase (UNG) digest followed by 95°C 1 min to destroy
UNG activity; Step 2: 60°C 30 minutes for reverse tran-
scription; Step 3: 50 Cycles of two-step PCR. Each cycle
included 95°C 30 sec (denaturation) followed by 60°C
30 sec (re-annealing and extension) Step 4: Slow ramp
from 60°C to 95°C to collect data for dissociation curves.
UNG was used to eliminate the possibility of carryover
contamination.
One well of RNA diluent was run as a negative control for
each RNA specimen. RNA diluent consisted of 10 mM
TRIS pH 8.0, 0.1 mM EDTA, 0.020 mg/mL poly r(A) RNA
(GE Healthcare), and 0.09% sodium azide (w/v). "High
input" and "low input" positive controls assessing expres-
sion of B2M were run on each plate. The target for the pos-
itive controls was human blood peripheral leukocyte total
RNA (Clontech) (100 ng for high input and 1 ng for low
input). After a run, the plate was inspected to see that Ct
values for high input and low input controls fell within a
specified range.
Samples were quantified using ribogreen, a nucleic acid
stain. After the concentration was determined, the sam-
ples were diluted in RNA diluent. 2 ng of RNA were used
in a 10 μl single-tube RT-PCR reaction for all assays except
IL-6, where 20 ng were used. All reactions were set up in
triplicate using a Biomek FX Laboratory Automation
Workstation (Beckman Coulter; Fullerton, CA). The prim-
ers used for each assay and gene accession numbers are
shown in Additional File 1.
Microarray procedures
Whole genome expression profiles were generated for all
samples at scheduled time points (Days 1, 14, 28, 90, and
180) in the subset of 22 subjects with the exception of the
Day 180 time point for subject 174 who died prior to the
end of the study. A total number of 109 microarrays were
hybridized. The Day 1, 90, and 180 samples were
obtained in January/February, April/May, and July/
August, respectively, and the mRNA was extracted in the
order received (see "RNA processing and quantitation").
Additionally, the samples were processed for microarrays
in two batches. The first batch was with samples up to Day
28, and the second with samples taken at Day 90 and Day
180. One microgram of total RNA from each blood sam-
ple was used to generate biotinylated cRNA, using the Agi-
lent Low RNA Input Linear Amplification procedure
(Version 2), with minor modifications (Agilent Technolo-
gies GmbH; Waldbronn, Germany); modification: bioti-
nylated UTP and CTP (Enzo Life Sciences; Farmingdale,
NY) were used for the in vitro transcription reaction, each
at a final concentration of 1 mM. cRNA was purified usingBMC Medical Genomics 2009, 2:33 http://www.biomedcentral.com/1755-8794/2/33
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Promega SV 96 DNA isolation kit (automated method), as
per the manufacturer's instructions (Promega Corpora-
tion, Madison, WI) or Qiagen's RNeasy purification kit
(manual method) (Qiagen GmbH; Hilden, Germany);
performance equivalency of the manual versus automated
methods were assessed in terms of yield, quality and
reproducibility with control universal human reference
RNA and control whole blood RNA (data not shown). The
cRNA samples were hybridized overnight to Affymetrix
U133 Plus 2.0 full genome oligonucleotide arrays and
then stained with Streptavidin-Phycoerythrin according to
the manufacturer's instructions (Affymetrix Inc, CA, USA).
Arrays were scanned using a GeneChip Scanner 3000
(Affymetrix) and signal intensities were calculated auto-
matically by GeneChip Operating Software (GCOS, ver-
sion 1.0; Affymetrix). Gene signal intensities were
computed using the MAS 5.0 algorithm (component of
GCOS 1.0 software). Signal intensities were normalized
using a quantile-quantile method [26]. All normalized
data were log2-transformed prior to analysis to down-
weight the influence of high expression values. The data
have been deposited in NCBI's Gene Expression Omnibus
(Edgar et al., 2002) and are accessible through GEO Series
accession number GSE16028 http://
www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE16028.
Statistical analysis
qRT-PCR
Units of cycle threshold (Ct), were used for the expression
data for all analyses. Outliers were defined as data points
falling ≥ 3 standard deviations (SD) outside the mean Ct
value, averaged over all time points and individuals,
within a gene. A graphical assessment was performed to
look for possible seasonal effects.
In addition to the normalization to total RNA input that
was performed, a strategy of normalization to four refer-
ence genes as a function of average gene expression
weighted by their variances was considered. Several
aspects of our study led us to conclude that reference gene
normalization was introducing several sources of system-
atic variability into the data. This variability was estimated
to be of appreciable size (analyses not shown) and was
not present in the total RNA normalized data because it
had been controlled for through study design. This varia-
bility was due to differences among reactions and differ-
ences across plates. The differences among reactions were
due to the necessity of having reference genes measured in
external reactions, because SYBR green assays cannot be
multiplexed. The differences among plates were due to
our 28-subject substudy design where a single gene was
assayed per plate, which allowed us to make all analyses
on within-plate comparisons only. It is known that the
precision that can be achieved with reference gene nor-
malization is limited by the variability present in the ref-
erence genes [27]. Since we could not increase the
precision of the immunomodulatory gene expression data
with the reference genes, and we had alternatively control-
led for appreciable amounts of systematic variability
through study design, the strategy of normalization to ref-
erence genes was abandoned.
A linear mixed model with fixed effects for gender, the
interaction of gender and time, and age, and a random
effect for subject was applied to the qRT-PCR data. From
this model, effects were tested and within-individual vari-
ation in gene expression over time was estimated. The
analysis was implemented using SAS Proc Mixed.
Microarray
An exploratory analysis was first performed to assess out-
liers and to determine if any clusters of subjects could be
observed. For this purpose, a correspondence analysis was
used. This analysis reduces the complexity of the data and
facilitates their interpretation by finding combinations of
genes that best explain the variability in the entire data set
[28]. The analysis was performed using the statistical
package XlStat 6.0 (Addinsoft; New York, NY).
Identification of differentially expressed genes
Of the potential 54,675 probe sets on the U133 Plus 2.0
microarray, 34,573 probe sets were present in at least one
sample (among the 109 microarrays hybridized) and were
used for the analysis. A statistical analysis was performed
to determine if expression profiles could indicate signifi-
cant gender, age, and time effects on gene expression. A
linear mixed-effect model [29] was built independently
for each of the 34,573 selected probe sets using log2-trans-
formed expression values and the analysis was imple-
mented using the function lme in SPLUS.
The model used can be expressed as:
where y is the normalized signal intensity of probe set p in
individual i at time t, βgender, βage, and βtime are respectively
the gender, age and time effects and α is the individual
random effect. The variances were denoted 
(between-subjects variance) for   and   (within-
subject variance) for εitp.
The significance of the effects was tested with t-tests.
Because of the numerous t-tests performed, we needed to
use a correction procedure, called the False Discovery Rate
(FDR) [30], which controls the expected proportion of
genes erroneously identified as differentially expressed
log ( ) ,, , 2 y gender age time itp p ip gender p i age p i time p =++ + + μα β β β  t ti t p + ε ,
σα,p
2
 αip σ ε,p
2BMC Medical Genomics 2009, 2:33 http://www.biomedcentral.com/1755-8794/2/33
Page 5 of 16
(page number not for citation purposes)
genes. For this study, an FDR of 5% was chosen. For each
probe set, a Shapiro test was performed to check whether
the linear mixed-effect models correctly fit the data. Only
17,329 probe sets for which the Shapiro P-value > 0.1%
were kept for further analysis.
Using the variance components estimated with the linear
mixed-effect model built for each of the 17, 329 probe
sets, we determined for each probe set p the intraclass cor-
relation coefficient among expression measures within a
subject over time by calculating the term  , with
 the variance computed between subjects, and 
the within-subject variance. Values of the correlation
range between 1 (i.e. no variation within subject) and 0
(i.e. high variation within subject).
We used the graphical representation proposed by Bland
and Altman [31] to determine the level of agreement
between gene expression values measured at different
time points. This type of graph plots the difference
between two measures as a function of their means. A
good agreement between different measures is observed
when the cloud of data points is located around 0 and
from the absence of a trend (i.e., slope of a robust linear
fit of the scatter plot close to 0). In the graphs shown the
differences on the vertical axis and the means on the hor-
izontal axis were not computed from the normalized
expression values but from the effects determined by the
linear mixed-effect model using time as a factor.
Infections
Subjects who experienced an adverse event had an addi-
tional sample collected following recovery from their
infections. Eighteen of the eighty subjects in the study had
a total of 24 infections. Infections in 7 patients were ongo-
ing at the time of a scheduled sample collection, and
infections in 11 patients ended within fourteen days
before a collection. The other seven infections in these
patients occurred outside these time frames and were not
included in this analysis. There was a wide range of times
between the scheduled blood draw and the recovery
blood draw (9–51 days), with most recovery period blood
draws occurring between 9–22 days. The time between the
end of the infection and the recovery period blood draw
ranged from 14–97 days, with most occurring between 14
to 23 days after the end of the event.
Results and Discussion
An overview of the study population and hematology
measures is presented first, followed by gene expression
data from both individuals who remained healthy
throughout the study, and those who experienced an
adverse event.
Study population characteristics
The healthy volunteers, 79 Caucasians and 1 Oriental,
were from eastern France and stratified into four cohorts
of 20 individuals each based on age (22 – 55 years and >
55 years) and gender (Table 1). The average age of males
versus females in each of the two age groups was similar:
34.5 ± 7.8 (mean ± SD) years for males versus 32.3 ± 9.5
years for females in the age 20 – 55 years group, and 59.7
± 3.1 versus 59.5 ± 4.5, respectively, in the over 55 group.
Patients were excluded from the trial if they took medica-
tion on a regular basis including birth control, hormone
replacement therapy, or herbal medicines or used
tobacco. The most frequently used medication for adverse
events that occurred during the study was paracetamol (30
subjects), followed by hexetedine (4), phloroglucinol (4),
and amoxicylline (4). One subject died from lung cancer
prior to the end of the study, while all other subjects com-
pleted the five scheduled visits on Days 1, 14, 28, 90, and
180 per protocol.
A subset of 28 individuals was chosen from the larger
study population and analyzed for the expression of
selected genes by qRT-PCR at four time points (Baseline,
Day 28, Day 90 and Day 180) (Table 1). Gene expression
of twenty-two subjects was assessed by high-density
microarray. Samples from eight subjects were analyzed on
both qRT-PCR and microarray platforms. All other sam-
ples in the two subsets were assayed on only one platform.
σα
σα σε
,
,,
p
pp
2
22 +
σα,p
2 σ ε,p
2
Table 1: Counts of patient samples by study, gender and age group.
Gender Age Group Main Study (n = 80) qRT-PCR Study (n = 28) Microarray Study (n = 22)
Female ≤ 55 Years 20 8 5
> 55 Years 20 7 7
Male ≤ 55 Years 20 5 5
> 55 Years 20 8 5BMC Medical Genomics 2009, 2:33 http://www.biomedcentral.com/1755-8794/2/33
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Hematology
Complete blood cell counts were obtained from all 80
subjects at all five time points. Neutrophils and lym-
phocytes, which together account for ~90% of white
blood cells, had similar distributions (Table 2 and Addi-
tional File 2). Most subjects had cell counts that were in
the lower half of the normal laboratory range for each cell
type. The within subject estimate of variability for neu-
trophils was 21% of the mean, and was 16% for lym-
phocytes. The ratio of the top to the bottom of the range
of values measured in the study was 6.3 for neutrophils
and 5.7 for lymphocytes.
Range of expression in selected immunomodulatory and 
reference genes by qRT-PCR
The RNA expression of eleven inflammatory markers
(CXCL1, HMOX1, ICAM1, IL1B, IL1RN, IL6R, MMP9,
PTGS2, SERPINE1, TGFB1, TNF), and four genes com-
monly used as reference genes in blood [32,33] (B2M, 18S
rRNA, GAPDH and PPP1CA), was evaluated by qRT-PCR
(Figure 1). The dynamic range of expression for all the
genes, both inflammatory and reference, was relatively
narrow. More specifically, 95% of all samples profiled for
CXCL1, HMOX1, IL1B, IL1RN, IL6R, PTGS2 and TNF had
a range of gene expression that fell within 1.5–2.5 Ct, an
approximately 4–6 fold range in transcript number, simi-
lar to the range for neutrophil and lymphocyte cell num-
bers. The gene that exhibited the highest variability was
TGFB1, in which 95% of all samples spanned 4.8 Ct, or a
28-fold range. Shapiro-Wilkes tests and Quantile-Quan-
tile analysis demonstrated that expression was approxi-
mately log-normally distributed for most targets, with
slight deviations in the tails (data not shown). Median
expression values for each immunomodulatory gene eval-
uated remained stable across each of the four time points
(Figure 2). Each qRT-PCR assay was performed using an
equivalent amount of RNA from all samples as input.
Normalizing against any of the four reference genes was
not effective at increasing precision of the observed
inflammatory gene expression (see Additional File 3).
McLoughlin et al.[15] evaluated expression of 48 inflam-
mation and immune-related transcripts by qRT-PCR in
healthy individuals at a single time point, including 10 of
the genes in the present study. They found a similarly nar-
row range of expression between subjects, including
standard deviation values that were within 0.2 Ct of that
observed here for most targets examined. Two of the tar-
gets with the highest variability in our study, MMP9 and
SERPINE1, showed similarly higher variability in that
study.
While PPP1CA and B2M had a relatively narrow range of
expression, GAPDH and 18S rRNA were more variable
among individuals than several of the immunomodula-
tory genes and therefore were not suitable for normalizing
the data set. GAPDH is elevated in T cells upon activation
[32,34] and can fluctuate in response to the changing
energy demands of cells [35]. The results presented here
support the notion that normalizing qRT-PCR data by
input RNA amount is a reasonable approach and may
introduce less variability than the use of a single reference
gene.
Variation in gene expression over time in samples 
hybridized on microarrays
Pairwise comparisons were performed to determine
whether the mean expression of each probe set on the
array varied between any two time points. None of the dif-
ferences seen at Days 14 and 28 compared to Day 1
Table 2: Hematology values of all subjects over all time points.
Cell Type Mean ± SD (109/L) Study Range (109/L) Lab Normal Range (109/L) Within-Subject Estimate of Variability (109/
L)
Total WBC 6.25 ± 1.43 3.3–12.3 4.5–10 0.84
Neutrophil 3.38 ± 1.07 1.4–8.8 1.8–7.5 0.70
Lymphocyte 2.16 ± 0.63 1.0–5.7 1.0–4.0 0.34
Monocyte 0.48 ± 0.13 0.03–1.09 0.20–1.00 0.09
Basophil 0.03 ± 0.02 0.01–0.16 0.00–0.20 0.02
Eosinophil 0.19 ± 0.12 0.04–0.69 0.04–0.50 0.05
Platelet 242 ± 54 129–596 150–400 23.11
The within-subject estimate of variability is the square root of the estimated residual variance from a linear mixed effects model with fixed effects 
for age, gender and time, and a random effect for subject.BMC Medical Genomics 2009, 2:33 http://www.biomedcentral.com/1755-8794/2/33
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remained significant after correcting for multiple compar-
isons (Figure 3). The Bland-Altman plot [31] (Figure 4)
shows there is no difference for samples separated by two
weeks (e.g. when Day 14 is compared to Day 1 or when
Day 28 is compared to Day 14). However, when Day 90
was compared to Day 180, 248 probe sets were found to
be differentially expressed, a higher number than would
be expected by random chance. Those 248 probe sets cor-
respond to 157 unique genes (excluding probe sets which
are not correctly mapped to the genome). Among those
157 genes, 66 genes were found associated with apoptotic
activities with log2-fold change ranging from -0.9 to 0.6.
It was not possible to draw a conclusion from the compar-
ison of the gene signal intensities measured at Day 1 and
at Day 90 (and at Day 1 and Day 180) as samples were
processed separately in two batches. The differences we
found may be the result of a seasonal effect, a true biolog-
ical effect, or experimental bias. The observed stability of
the gene expression profiles over a one-month period is
consistent with results from other studies [19,21].
Within-individual variability in gene expression over time
qRT-PCR
The estimate of total within-individual variance of the
eleven inflammatory genes shown in Table 3 reflects the
amount of deviation around the mean trend of gene
expression for a target gene over time. Total within-indi-
vidual variance estimates for the eleven inflammatory
Total ranges of immunomodulatory and reference gene expression (qRT-PCR study) Figure 1
Total ranges of immunomodulatory and reference gene expression (qRT-PCR study). The total range of gene 
expression is represented by box and whisker plots for immunomodulatory genes (blue) and reference genes (gold), for 28 
subjects at four time points. For each gene, the median is indicated by a horizontal line, the boxes indicate the range between 
the 25th to the 75th percentile, the whiskers indicate the range containing 1.5 times the interquartile range, and circles above 
the whiskers indicate outliers. Values beyond the range included by the whiskers are indicated as individual points. For ICAM1, 
three measurements were below the limit of quantification (Ct > 37).BMC Medical Genomics 2009, 2:33 http://www.biomedcentral.com/1755-8794/2/33
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genes ranged from 0.220 to 0.838 Ct
2, which was 1–3% of
the mean gene expression for a given gene. The two genes
with the highest within-individual variance estimates
were MMP9 and SERPINE1, while TNF had the smallest.
From the mixed effects models for each mRNA measured
by qRT-PCR, it was estimated that the correlation of gene
expression among time points in a single individual is less
than 50% for all genes assayed.
Microarray
One measure of the temporal variability of a gene is how
well its expression is correlated in any individual from one
point in time to the next. Using the variance components
estimated with the linear mixed effect models, we deter-
mined the correlation coefficient among expression meas-
ures within a subject over time for each of the 17,329
probe sets satisfying the Shapiro test (see Methods). Only
10% of the probe sets exhibited a coefficient > 0.4 (Figure
5). However, when only probe sets demonstrating robust
transcriptional expression with a log2-transformed signal
intensity ≥ 7 (raw signal intensity > 100) were considered,
the percentage with an intraclass correlation coefficient >
0.4 increased to 23%. The observation that those genes
expressed at low levels had the lowest intra-individual
correlations may be partly due to the known characteristic
of probe sets at the lower end of the quantitative range of
a microarray to have poorer reproducibility [36]. For
example, Dobbin et al. [37] found that RNA profiles from
tumor tissues had weaker correlations within an individ-
ual for those genes with low levels of expression. Inspec-
tion of the probe sets with the lowest correlation
coefficient (< 0.1) but still with a log2 expression signal
Immunomodulatory gene expression over time (qRT-PCR study) Figure 2
Immunomodulatory gene expression over time (qRT-PCR study). Median gene expression for each immunomodula-
tory gene is shown, with bars indicating the range from the 25th to the 75th percentile for all subjects.
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intensity ≥ 10 showed that ~90% either do not map to a
unique gene locus or do not map to the current version of
the human genome, as already observed by Zhang [38].
Age and gender effects
No genes analyzed by either qRT-PCR or microarray were
observed to be differentially regulated between the two
age groups. An age effect has been observed previously
with RNA profiling studies [19,21,39], and might have
been expected here, given the large number of genes meas-
ured. One explanation is that the broad age range within
a given group in this study may have prevented the detec-
tion of such an effect. Another is that blood might be less
susceptible to senescence effects when compared to other
tissues such as brain or muscle [40,41].
Females showed a small but statistically significant 1.3–
1.5-fold increase in gene expression relative to males for
the qRT-PCR targets CXCL1, HMOX1 and ICAM1 (see
Additional File 4. On the microarray, a total of 78 unique
genes were found to be differentially regulated by gender.
As expected, the XIST gene was found to be highly down-
regulated in males compared to females, with an average
log2-transformed signal intensity equal to 50 in females
and roughly 20 times lower expression in males. Fifteen of
the 78 genes had a log2-transformed signal intensity ≥ 7.0
(Table 4). For all of these genes, the mean difference
between sexes was less than 20%. Four X chromosome
genes were identified as differentially expressed. One of
these, RPS4X, is known to escape X inactivation [42] while
another, E1F1AX, has family members known to escape X
inactivation. Only 23 out of the 78 probe sets mapping on
the Y chromosome were present in at least one sample
and their log2-transformed signal intensities were always
below 7. The majority of the highly expressed probe sets
that were differentially regulated by gender are located on
autosomal chromosomes (Table 4). Among those genes,
flotillin1 (FLOT1), which was down-regulated in males
compared to females, was recently identified as an estro-
gen-responsive gene [43].
Effect of two severe adverse events on gene expression
A correspondence analysis (see Methods) was performed
on a set of 34,573 probe sets for all the samples from the
22 individuals studied with microarrays. This analysis
looked for combinations of genes that would explain the
overall variability in the data set and identify possible out-
liers. Almost all individuals across all time points were in
Time effect of Day 14 versus Day 1 (Microarray study) Figure 3
Time effect of Day 14 versus Day 1 (Microarray study). Each cross represents a probe set. The fold change is displayed 
on the x-axis (in log2 units); the p-values (corresponding to the t-tests performed) are displayed on the y-axis (in log10 units). 
Fold changes and p-values were computed with the linear mixed-effect model described in the Methods section. The left and 
right vertical lines represent fold changes equal to 0.5 and 2, respectively. The horizontal line represents an arbitrary type I 
error equal to 10-4.BMC Medical Genomics 2009, 2:33 http://www.biomedcentral.com/1755-8794/2/33
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close proximity to one another (Figure 6). However, data
points from two subjects, numbered 121 and 174, were
outside of the main cluster.
Subject 121 had anemia secondary to rectal bleeding with
a progressive drop in red cell count from baseline to Day
90. The subject's bleeding was stopped surgically on Day
100; on Day 180 red cell parameters had returned to the
normal range. The correspondence analysis data points on
Days 1, 14, and 28 are outside of the main cluster with the
Day 90 profile reaching a maximum distance from the
others. The Day 180 point has returned to normal. RBC-
associated genes with elevated expression levels included
ferrochetalase, carbonic anhydrase, ALAS2, erythrocyte
membrane protein band 4.2, glycophorin A and B, and
2,3-bisphosphoglycerate mutase. Some of the genes over-
expressed in subject 121, were correlated previously to
reticulocyte expressed genes: SLC4A1, EPP42, BCL2L1
and BNIp3L [21]. ALAS2 and carbonic anhydrase have
also been identified as genes that are down-regulated in
anemia during acute renal allograft rejection [44].
Subject 174 developed lung cancer and began chemother-
apy on approximately Day 70. She was a strong outlier in
the correspondence analysis on Day 90. Her monocyte
count on that day was severely depressed to 6.5% of the
baseline value (from 0.46 × 109/L to 0.03 × 109/L). All
other white cell types were within normal limits on Days
1, 14, 28, and 90. For subject 174, 31 genes were found to
be up-regulated. The gene ACRBP was elevated four- fold
above the other subjects on Day 90. ACRBP is a member
of the cancer/testis family of antigens, is immunogenic,
and has been detected in different tumor types [45]. The
growth arrest-specific (GAS)2-like 1 gene, an actin-associ-
ated protein expressed at high levels in growth-arrested
cells [46], was found to be 1.5-fold higher in subject 174,
compared to other individuals at Day 90. The changes in
gene expression observed in this subject correlated with
the onset of chemotherapy and may be largely attributa-
ble to treatment. However, for both these cases data is
required in larger numbers of patients to draw firm con-
clusions.
Effect of infection on gene expression
Eighteen of the eighty subjects in the study had a total of
24 infections. The infections were predominantly upper
respiratory infections (sinusitis, rhinitis, nasopharyngitis,
or pharyngitis), in addition to gastroenteritis, bronchitis,
Effect of time on gene expression (Microarray study) Figure 4
Effect of time on gene expression (Microarray study). A. Time effect within one month: Day 14 vs. Day 28. Each 
dot corresponds to a probe set. The differences on the vertical axis and the means on the horizontal axis were not computed 
from the normalized expression values but from the effects (βtime, p) determined by the linear model (see Methods), time being 
either Day 14 or Day 28; Day 1 was defined as baseline. The model used log2 values for the gene signal intensities. A robust 
local linear fit of the data is represented as a black line.BMC Medical Genomics 2009, 2:33 http://www.biomedcentral.com/1755-8794/2/33
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Table 3: Estimates of different components of within-individual variation (qRT-PCR study).
Gene Variance Within Time 
Point (Ct
2)
Covariance Between Time 
Points (Ct
2)
Total Within-Individual Var-
iance (Ct
2)
Correlation Between 
Time Points
CXCL1 0.155 0.108 0.263 0.410
HMOX1 0.150 0.097 0.247 0.393
ICAM1 0.512 0.064 0.576 0.111
IL1B 0.191 0.125 0.315 0.395
IL1RN 0.224 0.135 0.359 0.375
IL6R 0.292 -0.018 0.274 -0.066
MMP9 0.612 0.011 0.622 0.017
PTGS2 0.215 0.104 0.319 0.325
SERPINE1 0.503 0.336 0.838 0.401
TGFB1 0.259 0.084 0.344 0.245
TNF 0.150 0.070 0.220 0.318
Distribution of correlation coefficients among probe sets (Microarray study) Figure 5
Distribution of correlation coefficients among probe sets (Microarray study). Probe sets satisfying the Shapiro test 
were divided in two sets according to their average signal intensities: below or above log2 7. Distributions of the probe sets 
according to correlation coefficient values are displayed for both sets.BMC Medical Genomics 2009, 2:33 http://www.biomedcentral.com/1755-8794/2/33
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and skin infection and oral herpes simplex. Immunomod-
ulatory gene expression in subjects with active infection at
the time of sampling or within two weeks were slightly
elevated relative to the expression levels observed two
weeks after recovery and at all other time points (Figure
7). However, the expression of TGFB1 was still increased
in samples taken after recovery.
Conclusion
In this study with 80 healthy male and female subjects ≥
20 years of age, a normal range of gene expression was
established for 11 inflammation-related genes and four
housekeeping genes. Each gene was stably expressed,
independent of age and gender. There was no apparent
correlation between values more than three standard devi-
ations from the mean with adverse events or hematology
values. Nineteen subjects who had infections at the time
of or within two weeks before their scheduled blood
draws gave an additional sample two weeks after the reso-
lution of their infections. The samples collected during
the active infection showed slight elevations from the
expression levels seen in uninfected subjects. However,
the samples taken two weeks later showed increased
expression of TGFβ1.
Gene expression levels, as measured by microarray analy-
sis, appeared to be constant over one month; however,
over three months, a small percentage of genes appeared
to vary. We observed that intra-individual gene correla-
tions differ greatly depending on signal intensity. A small
proportion of genes were found to be differentially regu-
lated according to gender. Differential gene regulation by
age (in subjects 25–55 years of age versus subjects > 55
years of age) was not observed. Elevated expression levels
of red blood cell-associated genes were observed in one
subject who experienced progressive anemia secondary to
blood loss. Included among those genes were ferrocheta-
lase, carbonic anhydrase, ALAS2, erythrocyte membrane
protein band 4.2, glycophorin A and B, and 2,3-bisphos-
phoglycerate mutase.
Use of RNA expression studies in clinical trials
Several lessons can be drawn from this study regarding the
design and conduct of future clinical trials that test new
pharmacological entities and employ gene expression as
an assessment:
1. Estimates of sample sizes required to achieve a certain
power to detect changes in gene expression of a particular
magnitude can be calculated from the estimates of vari-
ance components given in the results section, results from
other studies, and the estimated effect size from in vitro
work.
2. Samples should be analyzed at the end of the experi-
ment rather than on an ongoing basis. A bias was intro-
Table 4: Genes differentially expressed between genders with log-transformed signal intensities ≥ 7 (Microarray study).
Gene Name Chromo-
some
Locus ID Affy ID  Fold Change Description
- - - 211074_at 0.82 Homo sapiens non-functional folate binding protein mrna, 
complete cds
EIF1AX X 1964 201019_s_at 0.86 Eukaryotic translation initiation factor 1a, x-linked
TMEFF2 M 23671 224321_at 0.87 Transmembrane protein with egf-like and two follistatin-like 
domains 2
FLOT1 6 10211 210142_x_at 0.87 Flotillin 1
EIF2S3 X 1968 224936_at 0.90 Eukaryotic translation initiation factor 2, subunit 3 gamma, 52 kda
RPS4X X 6191 213347_x_at 0.91 Ribosomal protein s4, x-linked
MGC71993 17 440400 224573_at 0.93 Similar to dna segment, chr 11, brigham + womens genetics 0434 
expressed
EEF1A1 1 1915 213477_x_at 1.05 Eukaryotic translation elongation factor 1 alpha 1
EEF1A1 6 1915 206559_x_at 1.07 Eukaryotic translation elongation factor 1 alpha 1
SPOP 17 8405 204640_s_at 1.07 Speckle-type poz protein
ERBB2IP 5 55914 217941_s_at 1.09 Erbb2 interacting protein
UHMK1 1 127933 224691_at 1.11 Kinase interacting with leukemia-associated gene (stathmin)
PP784 4 114932 212199_at 1.12 pp784 protein
HMGN4 6 10473 209787_s_at 1.13 High mobility group nucleosomal binding domain 4
C10orf45 10 83641 223058_at 1.13 Chromosome 10 open reading frame 45
HTATSF1 X 27336 202602_s_at 1.14 HIV tat specific factor 1
GNG2 14 54331 224964_s_at 1.14 Guanine nucleotide binding protein (g protein), gamma 2
HMGN4 6 10473 209786_at 1.17 High mobility group nucleosomal binding domain 4
HMGN4 6 10473 202579_x_at 1.20 High mobility group nucleosomal binding domain 4
XIST gene expression was found to be highly down-regulated in males compared to females. XIST does not appear in this table because the mean 
signal intensity was below the threshold of log27.BMC Medical Genomics 2009, 2:33 http://www.biomedcentral.com/1755-8794/2/33
Page 13 of 16
(page number not for citation purposes)
duced when samples from the present study were
processed and analyzed with different reagent lots over
time in sequential batches This type of bias, also recently
described by Yang et al. [47], could lead to the identifica-
tion of many artifacts among differentially expressed gene
sets.
3. Small elevations in inflammatory gene expression pro-
duced during upper respiratory infections generally return
to normal levels of expression within two weeks after the
infection has resolved.
4. Time and/or seasonal effects may be a factor in trials
lasting longer than one month.
5. Gender and age effects are not likely to be problematic
in populations from 20 to 65 years of age. The assessment
of gene expression profiles in children or very old individ-
uals might lead to different conclusions.
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Correspondence analysis of microarray samples Figure 6
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and 174). Subject 174 died prior to Day 180; therefore, that sample was not available for analysis. The three axes displayed 
explain 32% of the variance of the whole dataset. Each data point on the graph represents a projection of the expression pro-
file (34,573 probe sets in this case; see materials and methods for filtering of the data set) of one subject at a single time point. 
The distance between subjects reflects the distance between their entire gene expression profiles.BMC Medical Genomics 2009, 2:33 http://www.biomedcentral.com/1755-8794/2/33
Page 14 of 16
(page number not for citation purposes)
Authors' contributions
CK processed and quantified RNA from PAXgene tubes;
developed assays, performed experiments and analyzed
data for qRT-PCR, and drafted part of the manuscript. PM
performed the microarray experiments, analyzed data and
drafted part of the manuscript. CF, MT and MWS per-
formed the microarray experiments. AJ performed statisti-
cal analyses on the qRT-PCR data and drafted part of the
manuscript. GD performed statistical analyses on the
microarray data and drafted part of the manuscript. MN
performed statistical analyses on the adverse events and
hematology data. LS and TN performed experiments for
qRT-PCR. JC conceived of the study and its experimental
design, participated in the interpretation of results, and
helped prepare the manuscript.
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Comparison of 95% confidence intervals of mRNA levels during an infection, at recovery, and at all other time 
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an infection during the course of the study. Confidence intervals were obtained from estimates of mRNA levels during the 
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